FAQ on Medicus Pharma Ltd.'s Novel Treatment for Basal Cell Carcinoma

What is Medicus Pharma Ltd.’s new treatment for basal cell carcinoma?

Medicus Pharma Ltd. is developing a non-invasive treatment for basal cell carcinoma using a patented dissolvable microneedle patch that delivers a chemotherapeutic agent to kill tumor cells and induce an immune response to prevent recurrence.

Why is this treatment significant?

This treatment is significant because it offers a non-surgical option for basal cell carcinoma, addressing a significant unmet medical need and potentially transforming the $15 billion skin cancer treatment market.

How does the microneedle patch work?

The microneedle patch delivers doxorubicin, a chemotherapeutic agent, directly to the tumor cells on the skin, killing them and inducing a memory immune response to prevent cancer recurrence, all in a painless manner.

What are the results of the clinical trials so far?

Preliminary trial results are promising, with a Phase I study meeting its primary safety and tolerability objectives, and an interim analysis of the Phase 2 study showing over 60% complete clinical clearance in subjects.

When is the treatment expected to be available?

Medicus plans to submit an interim analysis to the FDA in Q2 2025 as part of a package seeking fast-track approval, indicating that the treatment could be available after successful completion of clinical trials and regulatory approval.

Where is the clinical study being conducted?

The Phase 2 clinical study is being conducted at nine sites in the US and two in Europe, with plans to expand, and a separate study is approved to commence in the UAE at four sites.

Who is involved in the development of this treatment?

Medicus Pharma Ltd., through its subsidiary SkinJect Inc., is leading the development, with clinical trials involving patients with basal cell carcinoma and regulatory bodies like the FDA and UAE Department of Health.

What are the implications of this treatment for the skin cancer market?

This treatment could upend the $15 billion skin cancer market by providing a non-invasive, effective alternative to surgery, reducing patient discomfort and healthcare costs associated with surgical procedures.

How does this treatment compare to current options for basal cell carcinoma?

Current options primarily involve surgical procedures like excision or Mohs surgery, which are invasive. Medicus’s microneedle patch offers a non-invasive, potentially more comfortable and equally effective alternative.

What should people know about this treatment?

People should know that this treatment is still under clinical development, showing promising early results, and could offer a non-surgical option for basal cell carcinoma in the near future, pending regulatory approval.